Share this Page:
The following interviews with kidney cancer experts were recorded by Practice Update and UroTodayat the American Society for Clinical Oncology (ASCO) genitourinary (GU) conference in San Francisco in February 2019.
Pembrolizumab and axitinib as first-line therapy
Key data from ASCO GU 2019 on mRCC
Frontline RCC treatment from ASCO GU 2019: Practice implications
Pembrolizumab for non-clear cell RCC
Tivozanib for refractory advanced RCC
Patient perspectives on cytoreductive nephrectomy after the CARMENA trial